{"id":132,"date":"2020-05-03T16:05:20","date_gmt":"2020-05-03T16:05:20","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=132"},"modified":"2020-05-03T16:05:20","modified_gmt":"2020-05-03T16:05:20","slug":"30-april-2020favipiravir-early-viral-clearance-contributed-to-the-improvement-of-chest-imaging-on-day-14","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/30-april-2020favipiravir-early-viral-clearance-contributed-to-the-improvement-of-chest-imaging-on-day-14\/","title":{"rendered":"(30 April 2020)Favipiravir &#8211; early viral clearance contributed to the improvement of chest imaging on Day 14"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.eng.2020.03.007<\/p>\n<p class=\"\">In this open-label comparative controlled study of patients with COVID-19, those treated with Favipiravir (FPV) appeared to have faster viral clearance and better chest imaging change on day 14 than patients treated with LPV\/RTV.&nbsp; Fewer adverse events were found in the FPV arm than in the control arm. FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. These preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study https:\/\/doi.org\/10.1016\/j.eng.2020.03.007 In this open-label comparative controlled study of patients with COVID-19, those treated with Favipiravir (FPV) appeared to have faster viral clearance and better chest imaging change on day 14&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/30-april-2020favipiravir-early-viral-clearance-contributed-to-the-improvement-of-chest-imaging-on-day-14\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(30 April 2020)Favipiravir &#8211; early viral clearance contributed to the improvement of chest imaging on Day 14&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/132"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=132"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/132\/revisions"}],"predecessor-version":[{"id":134,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/132\/revisions\/134"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}